SR One Capital Management, LP — 13F Holdings & Portfolio
CIK 1910264 · latest 13F-HR filed 2026-08-12
SR One Capital Management, LP manages $1.04B in 13F-reported U.S. long-equity assets across 15 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MANE (28.42%), ZBIO (12.31%), CRSP (10.70%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 2; 7 existing positions rose in reported value and 3 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-12
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 95.1%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
SUITE 200
REDWOOD CITY, CA 94063
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| DADOO, RAJEEV, NMN Control | LIMITED PARTNER; MANAGING PARTNER; COO since Oct 2019 | 25–50% | Individual |
| GEORGE, SIMEON, JOHN Control | LIMITED PARTNER; CEO; MANAGING PARTNER since Oct 2019 | 25–50% | Individual |
| KEOUGH, SASHA, OSHRINE Control | CCO since Jan 2023 | Less than 5% | Individual |
| MACADAM, JAMES, CHALMERS Control | CFO since Jan 2023 | Less than 5% | Individual |
| SR ONE CAPITAL MANAGEMENT, LLC Control | GENERAL PARTNER since Oct 2019 | Less than 5% | Domestic Entity |
| GEORGE, SIMEON, JOHN Control Indirect owner via SR ONE CAPITAL MANAGEMENT, LLC | MANAGING MEMBER since Oct 2019 | 75% or more | Individual |
Ownership & leadership changes · 4 filings with changes since Nov 4, 2019
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedFOY, MATTHEW, JAMES · LIMITED PARTNER; COO · 10–25% · control person · listed since Oct 2019
- ChangedDADOO, RAJEEV, NMN · title LIMITED PARTNER AND MANAGING PARTNER → LIMITED PARTNER; MANAGING PARTNER; COO
- AddedGEORGE, SIMEON, JOHN · MANAGING MEMBER · 75% or more · indirect via SR ONE CAPITAL MANAGEMENT, LLC · control person
- AddedSR ONE CAPITAL MANAGEMENT, LLC · GENERAL PARTNER · Less than 5% · control person
- ChangedDADOO, RAJEEV, NMN · title MANAGING PARTNER → LIMITED PARTNER AND MANAGING PARTNER
- ChangedFOY, MATTHEW, JAMES · title PARTNER; COO → LIMITED PARTNER; COO
- ChangedGEORGE, SIMEON, JOHN · title PARTNER; CEO → LIMITED PARTNER; CEO; MANAGING PARTNER
- AddedMACADAM, JAMES, CHALMERS · CFO · Less than 5% · control person
- ChangedDADOO, RAJEEV, NMN · title PARTNER → MANAGING PARTNER
- AddedKEOUGH, SASHA, OSHRINE · CCO · Less than 5% · control person
- ChangedDADOO, RAJEEV, NMN · title PARTNER; CCO → PARTNER
- ListedDADOO, RAJEEV, NMN · PARTNER; CCO · 25–50% · control person
- ListedFOY, MATTHEW, JAMES · PARTNER; COO · 10–25% · control person
- ListedGEORGE, SIMEON, JOHN · PARTNER; CEO · 25–50% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Veradermics, Inc.$143.6M +94.7%
- Zenas BioPharma, Inc$29.4M +29.8%
- Design Therapeutics, Inc.$25.0M +36.0%
- CRISPR Therapeutics AG$14.2M +14.7%
- Alumis Inc.$12.0M +27.7%
Top Trims
- ORIC Pharmaceuticals, Inc.-$8.5M -14.5%
- Oculis Holding AG-$8.2M -47.8%
- enGene Holdings Inc.-$3.8M -74.6%
New Positions
- Avalyn Pharma, Inc$108.9M
- Odyssey Therapeutics, Inc.$71.0M
- Mobia Medical, Inc$26.6M
SR One Capital Management, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Veradermics, Inc. | MANE | 922967104 | $295.3M | 28.42% | 2,401,868 | SH |
| 2 | Zenas BioPharma, Inc | ZBIO | 98937L105 | $127.9M | 12.31% | 5,037,854 | SH |
| 3 | CRISPR Therapeutics AG | CRSP | H17182108 | $111.2M | 10.70% | 2,038,763 | SH |
| 4 | Avalyn Pharma, Inc | AVLN | 05348Y105 | $108.9M | 10.48% | 3,308,649 | SH |
| 5 | Design Therapeutics, Inc. | DSGN | 25056L103 | $94.4M | 9.09% | 6,526,476 | SH |
| 6 | Odyssey Therapeutics, Inc. | ODTX | 67613T104 | $71.0M | 6.83% | 3,794,883 | SH |
| 7 | Alumis Inc. | ALMS | 022307102 | $55.2M | 5.31% | 1,959,896 | SH |
| 8 | ORIC Pharmaceuticals, Inc. | ORIC | 68622P109 | $50.0M | 4.81% | 4,615,384 | SH |
| 9 | Mineralys Therapeutics Inc. | MLYS | 603170101 | $42.2M | 4.06% | 1,563,966 | SH |
| 10 | ARS Pharmaceuticals, Inc. | SPRY | 82835W108 | $32.1M | 3.09% | 4,012,903 | SH |
| 11 | Mobia Medical, Inc | MOBI | 60705V103 | $26.6M | 2.56% | 1,986,072 | SH |
| 12 | Nkarta, Inc. | NKTX | 65487U108 | $9.4M | 0.91% | 3,333,333 | SH |
| 13 | Oculis Holding AG | OCS | H5870P102 | $8.9M | 0.86% | 641,022 | SH |
| 14 | Ultragenyx Pharmaceutical Inc. | RARE | 90400D108 | $4.6M | 0.44% | 137,753 | SH |
| 15 | enGene Holdings Inc. | ENGNW | 29286M105 | $1.3M | 0.12% | 747,750 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-12 | $1.04B | 15 | 0001193125-26-347065 |
| 2026-03-31 | 2026-05-14 | $915.4M | 14 | 0001193125-26-224136 |
| 2025-12-31 | 2026-02-12 | $706.4M | 13 | 0001193125-26-048808 |
| 2025-09-30 | 2025-11-12 | $691.4M | 12 | 0001193125-25-277769 |
SUITE 200
REDWOOD CITY, CA 94063